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OBJECTIVE: The purpose of this study is to develop
cost-effectiveness methodology in the context of a simul-
taneous modeling framework that provides consistent
point and interval estimations. 
METHODS: A system of cost and effectiveness equations
is suggested to model the simultaneity of the underlying
cost and effectiveness variables, directly producing a mar-
ginal-effect measure of the incremental cost-effectiveness
ratio of two competing medical interventions in an evalua-
tive study. Empirical estimation of the simultaneous cost-
effectiveness model was conducted using a feasible non-
linear least squares estimation method. A simulation
analysis of hypothetical data was performed to show the
superior performance of the marginal-effect approach,
relative to the traditional average-effect approach. 
RESULTS: Traditional average-effect approach has two
shortcomings. First, it assumes two strong conditions:
truly random distributions of all the significant non-
intervention variables (both observed and unobserved)
across a study’s intervention and control groups, and the
independence of cost and effectiveness variables. Second,
it does not give a confidence interval, an important mea-
sure to assess the stochastic nature and robustness of
point estimates. In contrast, the simultaneous marginal-
effect approach imposed no restrictions on the random-
ness of the across-group distributions of all the variables.
Furthermore, it takes into account the simultaneity of
cost and effectiveness functions in estimation. The simu-
lation analysis showed that the marginal-effect approach
is significantly more robust, efficient, and unbiased than
the average-effect approach in predicting the population
true parameters assumed. 
CONCLUSION: The simultaneous marginal-effect ap-
proach should be chosen over the conventional average-
effect approach whenever data allows in assessing the
cost-effectiveness of competing interventions in medical
decision-making.
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OBJECTIVE: To understand the evolution and current
state of the field, we conducted a formal audit of published
cost-utility analyses (CUAs). The objectives were to: 1) de-
velop and test an auditing process for judging the transpar-
ency and uniformity of analyses; 2) examine variations in
practices in previously published studies; 3) determine
whether methods used have been consistent with standard
recommendations; and 4) investigate whether analyses
have been improving over time. 
METHODS: A systematic search of the English-language
medical literature identified 228 original CUAs published
from 1976 through 1997. Each article was audited inde-
pendently by two trained readers using a standard data
collection form to determine quality, completeness, and
clarity. Data were collected on: 1) background; 2) framing;
3) cost estimation; 4) effectiveness estimation; 5) QALY
estimation; 6) reporting of results; 7) discussion; 8) cost/
QALY ratios; and 9) readers’ subjective assessment of
overall quality. 
RESULTS: Cost-utility analyses have covered a wide range
of diseases and interventions. Most studies have ade-
quately described the comparator intervention (83%), ap-
propriately conducted incremental analysis (86%), dis-
counted both costs and QALYs (72%), and performed
sensitivity analysis (89%). Only 52% clearly stated the
study perspective; 34% did not disclose the funding
source. Methods for estimating costs, effectiveness, and
QALYs have varied widely. The quality of published anal-
yses has improved somewhat over time. 
CONCLUSION: The results reveal an active and evolving
field, but also underscore the need for more consistency
and transparency. Concerns about the comparability and
credibility of analyses would be allayed with more uniform
methods for performance and reporting. Better peer re-
view and independent, third-party audits of the kind used
here would likely help in this regard.
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Pharmacoeconomics is one of the most rapidly developing
sciences in Western countries. The principles of economic
analysis are widely accepted and used. In Russia the situa-
tion is almost completely the reverse. The economic im-
pact of new therapies is usually ignored while the use of
drugs is dictated by tradition and price The result is non-
evidence-based and non-economically-based clinical prac-
tice. The list of best selling drugs in Russia today includes
several drugs unheard of in the West. Many drugs which
are in high demand have no proven efficacy. Inadequate
healthcare financing has put procedure on public purchas-
ing authorities and prescribers to supply the cheapest
drugs and generic equivalents sometimes of poor quality.
One of the ways to solve the problem is to implement the
principles of economic evaluation to policy-making and
general practice though the lack of specialists in pharma-
coeconomics is an obvious obstacle. Despite several signs
of improvement there is still a lot to do. During the last
several years a few steps were made to accomplish this
goal. They include the creation of Center of Evidence-
Based Medicine and Russian branch of ISPOR. Today their
main task seems to be dissemination of knowledge through
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the preparation of scientific publications, guidelines, lec-
tures, workshops etc. At the present time the Russian pro-
fessionals actively participate in international randomized
clinical trials but the experience of pharmacoeconomic and
outcome research is very limited. So in the nearest future it
is important to organize adequate economic trials to show
the advantages and the disadvantages of existing health-
care interventions. The independence of investigators may
be guaranteed by governmental funding of such trials
though participation of the pharmaceutical industry seems
to be more real in the present economic crisis.
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Previous research into the usefulness of cost-effectiveness
information in managed care has had a narrow scope.
This research has been limited to the level of importance
that managed care directors place on pharmacoeconomic
(PE) data, the types of studies that MCOs prefer to re-
view and the future use of this type of information. 
OBJECTIVES: The purpose of this study was to ascertain
1) the level of importance that PE information has on the
speed of formulary approval, 2) the relationship between
the cost of therapeutic agents and PE information, 3) the
relationship between the time of market entry/number of
competitor products and requirements for PE informa-
tion, and 4) the importance of PE information by thera-
peutic classification. 
METHODS: A telephone survey of 41 randomly selected
pharmacy directors and medical directors was conducted
to elicit their attitudes towards PE information. 
RESULTS: PE information was somewhat/very impor-
tant in influencing the speed of formulary pull-through in
51.2% of respondents. The majority of respondents felt
that PE information was not important when drug acqui-
sition cost was less than $100; however, its importance
increased as acquisition cost increased. Respondents felt
that the time of market entry influenced the level that
they placed on PE information. When there were no sim-
ilar agents on formulary 73.1% felt that PE data was
somewhat/very important, when there were ten similar
agents on formulary 48.8% of respondents felt that PE
information was somewhat not/not important. Respon-
dents indicated that the therapeutic areas of depression,
asthma, rheumatoid arthritis, pain control, and hyperten-
sion were areas where cost-effectiveness analysis would
be most useful. 
CONCLUSIONS: PE information is relevant to managed
care decision-making and it is influenced by the drug ac-
quisition cost, the number of competitor drugs on market
and the therapeutic area under consideration.
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OBJECTIVE: The purpose of the study was to determine
the potential savings to the Portuguese National Health
System if the utilization of generic medications increased.
METHODS: The total sales of the 100 brand names with
the highest sales to the Portuguese National Health Sys-
tem in 1997 were examined to determine which ones had
a generic equivalent on the market. These were then sub-
stituted in four different scenarios where the substitution
levels were 10%, 25%, 50%, and 100% and the total
sales after substitution was calculated for each scenario.
Finally, the potential savings were determined. 
RESULTS: Of the 100 brand names with the highest sales
to the Portuguese National Health System in 1997, 18
had generic equivalents on the market. When these were
substituted at a 10% level, the estimated savings were
833.037.000 PTE (3.2%). When the substitution levels
were 25%, the estimated savings were 2.082.592.000 PTE
(8.0%). When the substitution level was 50%, the esti-
mated savings were 4.165.185.000 PTE (16.0%). When
the substitution level was 100%, the estimated savings
were 8.330.370.000 PTE (32.0%). 
CONCLUSION: Our pharmacoeconomic analysis dem-
onstrated that the Portuguese National Health System
can save a significant amount of its pharmacy budget by
increasing the utilization of generic medications.
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OBJECTIVE: The aim of this study was to study the
present situation regarding perceptions, understanding
and attitude towards pharmacoeconomics in Norway
among employees within the pharmaceutical authorities
and the pharmaceutical industry, prior to the introduc-
tion of pharmacoeconomic guidelines. 
METHODS: Personal interviews of employees working
with medicines on various levels were conducted, 47
from the authorities and 47 from the industry. The inter-
view included questions regarding associations to various
pharmacoeconomic expressions and questions about atti-
tude towards within which areas that pharmacoeconomic
analyses could be of use and the extent to which pharma-
coeconomic analyses should be implemented. The quanti-
tative data was handled in the statistical programme
SPSS. Factor analysis was used to find correlation among
some of the attitude questions. 
